Clinical trials: MMR Vaccine
Japanese Encephalitis, Measles
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
This study is designed to compare the immunogenicity of Japanese encephalitis chimeric virus vaccine (JE-CV) and measles-mumps-rubella (MMR)vaccine when given together or when given at separate visits 6 weeks apart in toddlers…
- Conditions
- Japanese Encephalitis, Measles, Mumps, Rubella
- Trial name
- NCT01188343
- Testing
- Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
- Where
- 3 sites in Taiwan
- Volunteers
- 542 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Glioma
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Glioblastoma (GBM) is the most malignant primary intracranial tumor with a median survival of about 18 months, and new therapies are urgently needed.
- Trial name
- NCT06043232
- Testing
- DC vaccine
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Huashan Hospital
Varicella, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
As measles-mumps-rubella (MMR) vaccination is established as routine childhood practice in most industrialised countries and varicella vaccination is now being introduced in many countries during the second year of life, a…
- Conditions
- Varicella, Rubella, Measles, Mumps
- Trial name
- NCT00353288
- Testing
- MeMuRu-OKA (study vacc), MMR, Varicella vacc (control)
- Where
- 39 sites in France, Germany and 1 more
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Making Decisions About the Measles-Mumps-Rubella Vaccine
The goal of this study is to determine whether a computer-based intervention that delivers individually-tailored educational messages about the MMR vaccine increases MMR vaccine-hesitant parents' intentions to have their children…
- Conditions
- Measles, Mumps, Rubella, MMR Vaccination
- Trial name
- NCT01369394
- Testing
- Behavioral: Computer-based tailoring system
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Vaccination Failure, Vaccine Response Impaired
Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
The current recommendation for a full course of measles-mumps-rubella-(varicella) vaccine (MMR(V)) is two doses. The problem is, many individuals within the vaccinated cohort show antibody levels that are below the level…
- Trial name
- NCT05923970
- Testing
- Serology for antibody levels - Baseline, Serology to assess cell mediated immune (CMI) response - Baseline, Serology for antibody levels - Post third dose of MMR vaccine
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University of Alberta
Haemophilus Influenzae Type b, Neisseria Meningitidis
Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of a booster dose of the candidate Hib-MenC conjugate vaccine given concomitantly with measles, mumps and rubella (MMR) vaccine, versus…
- Trial name
- NCT00263653
- Testing
- Haemophilus influenzae type b- and meningococcal (vaccine)
- Where
- 16 sites in Spain
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Measles, Mumps, and Rubella (MMR) Immunity in College Students
This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar…
- Conditions
- Measles, Mumps, Rubella
- Trial name
- NCT00962819
- Testing
- MMR vaccine
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Sri Edupuganti, MD MPH
Covid19
Biomarkers of Trained Immunity Following MMR Vaccination
This is a substudy of NCT04333732. The goal of this sub-study is to identify and characterize biomarkers of trained immunity by measuring, in vitro, immune responses to heterologous products, especially viral associated products…
- Trial name
- NCT04646239
- Testing
- Heterologous stimuli, Neutralization assay
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Rubella, Mumps
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore.
- Conditions
- Rubella, Mumps, Measles
- Trial name
- NCT00388440
- Testing
- MMR vaccine (Priorix)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Polio, Measles
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.
- Conditions
- Polio, Measles, Rubella, Mumps
- Trial name
- NCT07338851
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Mumps, Rubella
Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
This study will collect data on the safety of the MMRV vaccine (Priorix-Tetra™) used in routine practice in children aged 12 months to 12 years living in the Philippines.
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT01738841
- Testing
- Priorix-Tetra™, Safety data collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
ProQuad Dose Selection Study (V221-011)(COMPLETED)
A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00986232
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: M-M-R II, Comparator: PUVV
- Volunteers
- 1,551 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer
By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.
- Trial name
- NCT07539155
- Testing
- Intratumoral MMR Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Haemophilus Influenzae Type b, Neisseria Meningitidis
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
The purpose of the primary phase of the study is to demonstrate the non-inferiority of a single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine when given in the second year…
- Trial name
- NCT00326118
- Testing
- Haemophilus influenzae type b and meningococcal serogroup C (vaccine), Priorix™, Hiberix™
- Where
- 7 sites in Australia
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine Response Impaired
Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines
This study evaluates seroconversion against measles, mumps, rubella and yellow fever following vaccination. One-third of children will receive both yellow fever and measles, mumps, and rubella (MMR) vaccines on the same day; one…
- Trial name
- NCT03368495
- Testing
- Co-administration of MMR/YF, MMR followed by YF, YF followed by MMR
- Where
- 4 sites in Argentina
- Volunteers
- 851 people, healthy volunteers welcome
- Sponsor
- Alba Maria Ropero
Sepsis Syndrome
Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis
The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers…
- Trial name
- NCT04475081
- Testing
- MMR vaccine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Covid-19 Pandemics, Tuberculosis
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
This study is a non-randomized observation and comparison of immune response between bacteriologically confirmed TB patients under treatment cohort who received COVID-19 vaccine (n=54) vs healthy individuals (n=54).
- Trial name
- CVTB (NCT05571735)
- Testing
- Pfizer-BioNTech COVID-19 vaccine, AstraZeneca vaccine, Janssen Ad26.COV2.S COVID-19 vaccine
- Where
- Thailand
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15…
- Trial name
- NCT02184572
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 95 sites in United States, Estonia and 3 more
- Volunteers
- 1,742 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Polio, Diphteria, Tetanus and Pertussis
Study of Concomitant Administration of the sIPV and DTaP or MMR
This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and DTaP or MMR in infants aged 2 months.
- Conditions
- Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine
- Trial name
- NCT06920069
- Testing
- sIPV, DTaP, bOPV 1,3
- Where
- 9 sites in China
- Volunteers
- 2,640 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences